glecaprevir/pibrentasvir

AbbVie, Enanta post stellar hep C PhIII data, but no one is cheering
AbbVie, Enanta post stellar hep C PhIII data, but no one is cheering
Endpoints
AbbVie
Enanta
hepatitis C
glecaprevir/pibrentasvir
Flag link:
AbbVie's Hepatitis C Treatment Under Priority Review in Japan
AbbVie's Hepatitis C Treatment Under Priority Review in Japan
Yahoo/GuruFocus
AbbVie
hepatitis C
Japan
glecaprevir/pibrentasvir
Flag link:
U.S. FDA Grants Priority Review to AbbVie for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
U.S. FDA Grants Priority Review to AbbVie for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
Yahoo
FDA
AbbVie
glecaprevir/pibrentasvir
G/P
hepatitis C
Flag link:
AbbVie Files for Approval of Hepatitis C Treatment in the US
AbbVie Files for Approval of Hepatitis C Treatment in the US
Yahoo/GuruFocus
AbbVie
hepatitis C
glecaprevir/pibrentasvir
Flag link:
After The Deluge, Hep C Players Look For Opportunity
After The Deluge, Hep C Players Look For Opportunity
Seeking Alpha
hepatitis C
Gilead Sciences
AbbVie
Epclusa
glecaprevir/pibrentasvir
sofosbuvir/velpatasvir
Flag link:
AbbVie reports positive 8-week data in HCV
AbbVie reports positive 8-week data in HCV
BioPharma Dive
AbbVie
hepatitis C
glecaprevir/pibrentasvir
Flag link:
AbbVie Receives FDA Ranking for Hepatitis C Therapy
AbbVie Receives FDA Ranking for Hepatitis C Therapy
Yahoo/GuruFocus
AbbVie
FDA
hepatitis C
glecaprevir/pibrentasvir
Flag link: